Shares of Mumbai-based infrastructure EPC company Vikran Engineering Ltd. started trading on Wednesday, September 3, 2025, opening at ₹99.70 on the BSE, offering a slight premium of 2.78% over its IPO price of ₹97. On the NSE, the stock listed at ₹99, reflecting a modest market debut.
Shares of Anlon Healthcare, a company specialising in pharmaceutical intermediates and active pharmaceutical ingredients (APIs), began trading on Dalal Street on Wednesday, 3 September 2025. The stock opened at ₹92 on the NSE, reflecting a modest movement from its issue price of ₹91 per share. On the BSE, it traded around ₹91.5, showing a small increase of 0.55% from the listing price.
Robust Investor Response to IPO
The Anlon Healthcare IPO, valued at ₹121 crore, was entirely a fresh issue, comprising 13.3 million equity shares. The issue was well-received by investors, with strong subscription numbers reported across different categories.
Registrar and Lead Manager
Kfin Technologies was appointed as the registrar for the IPO, while Interactive Financial Services acted as the sole book-running lead manager, ensuring smooth processing and allotment of shares.
About Anlon Healthcare
Incorporated in 2013, Anlon Healthcare focuses on the production of pharmaceutical intermediates and APIs. Its products cater to medicines, nutraceuticals, personal care, and veterinary applications, manufactured according to Indian and international pharmacopoeia standards, including IP, BP, EP, JP, and USP. The company has also obtained Drug Master File (DMF) approvals from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs.
Use of IPO Proceeds
According to the Red Herring Prospectus, the net proceeds from the fresh issue will be utilised for the company’s planned expansion, repayment of debt, working capital requirements, and general corporate purposes.
Positioning in the Pharmaceutical Sector
With its listing on the NSE SME, Anlon Healthcare enters the public market at a stable valuation, reinforcing its presence in India’s pharmaceutical intermediates and APIs space. The company’s focus on quality compliance, diverse product offerings, and strategic expansion plans positions it well for future growth.
Conclusion
The debut of Anlon Healthcare on Dalal Street marks an important step for the company and its investors. With a successful IPO and strong fundamentals, the firm is poised to expand its operations and strengthen its role in India’s pharmaceutical sector.
If you are exploring more investment opportunities, check out our dedicated page on upcoming IPO listings to stay updated on the latest market offerings.
